The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications

DMARD (disease-modifying antirheumatic drugs)

Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications

Change in the Disease Activity Score - 28 (DAS-28) [ Time Frame: Every 3 months up to 6 months, then every 6 months up to 24 months ]

The DAS - 28 is calculated using the number of swollen (SJC) and tender (TJC) joints out of 28, the erythrocyte sedimentation rate (ESR) and the patient's global assessment of disease activity using a 100 mm visual analogue scale (VAS)

Secondary Outcome Measures
:

Duration of Morning Stiffness (min) [ Time Frame: Every 3 months up to 6 months, then every 6 months up to 24 months ]

This is ascertained by the treating physician during the patient assessment and is measured in minutes

This is a self-administered questionnaire comprised of 10 items assessing a patient's skin and problems associated with skin disease. The 10 questions in the DLQI converge into six domains that measure symptoms and feelings, daily activities, leisure, work and / or school, personal relationships and satisfaction with treatment.

Health Assessment Questionnaire - Disability Index (HAQ-DI) [ Time Frame: Every 3 months up to 6 months, then every 6 months up to 24 months ]

Self-administered questionnaire measuring the patient's functional ability during the last week.

Patient Global Assessment of Disease Activity (VAS and 5 Point Scale) [ Time Frame: Every 3 months up to 6 months, then every 6 months up to 24 months ]

A 100 mm VAS with 0 indicating lowest disease and 100 highest disease activity and a five point Likert Scale (0 - 4) that is completed by the patient at the physician's office

Physician Global Assessment of Disease Activity (VAS and 5 Point Scale) [ Time Frame: Every 3 months up to 6 months, then every 6 months up to 24 months ]

This is a 100 mm VAS with 0 indicating lowest disease and 100 highest disease activity a five point Likert Scale (0 - 4) that is completed by the physician during the patient examination

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 99 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Offices of community rheumatologists & dermatologists

Criteria

Inclusion Criteria:

Adult >= 18 years old

Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel

Active Psoriatic Arthritis (PsA) with three (3) or more tender and swollen joints as well as active psoriatic skin lesions or confirmed history of psoriasis

Inadequate response or non-tolerant to current disease-modifying antirheumatic drugs (DMARD) based treatment for PsA

Exclusion Criteria:

Currently participating in another prospective study including controlled clinical trials and observational studies

Patient cannot or will not sign informed consent

Stable disease with adequate tolerance and response to current treatment and no change in treatment is indicated